XML 46 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information (Tables)
 9 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Disaggregation of Revenue [Table Text Block]
Three Months Ended March 31,
(in millions)20222021
Pharmaceutical Distribution and Specialty Solutions (1) (2)$40,723 $34,903 
Nuclear and Precision Health Solutions234 201 
Pharmaceutical segment revenue
40,957 35,104 
Medical distribution and products (3)3,283 3,638 
Cardinal Health at-Home Solutions601 536 
Medical segment revenue
3,884 4,174 
  Total segment revenue44,841 39,278 
Corporate (4)(5)(3)
Total revenue$44,836 $39,275 
Nine Months Ended March 31,
(in millions)20222021
Pharmaceutical Distribution and Specialty Solutions (1) (2)$121,501 $106,859 
Nuclear and Precision Health Solutions653 593 
Pharmaceutical segment revenue
122,154 107,452 
Medical distribution and products (3)10,296 10,805 
Cardinal Health at-Home Solutions1,822 1,636 
Medical segment revenue
12,118 12,441 
  Total segment revenue134,272 119,893 
Corporate (4)(11)(12)
Total revenue$134,261 $119,881 
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]
The following tables present revenue by geographic area:
Three Months Ended March 31,
(in millions)20222021
United States$43,710 $38,089 
International1,131 1,189 
  Total segment revenue44,841 39,278 
Corporate (1)(5)(3)
Total revenue$44,836 $39,275 
Nine Months Ended March 31,
(in millions)20222021
United States$130,933 $116,425 
International3,339 3,468 
  Total segment revenue134,272 119,893 
Corporate (1)(11)(12)
Total revenue$134,261 $119,881 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following tables present segment profit by reportable segment and Corporate:
Three Months Ended March 31,
(in millions)20222021
Pharmaceutical (1)$487 $511 
Medical59 174 
Total segment profit546 685 
Corporate(643)(212)
Total operating earnings/(loss)$(97)$473 
Nine Months Ended March 31,
(in millions)20222021
Pharmaceutical (1)$1,319 $1,326 
Medical232 640 
Total segment profit1,551 1,966 
Corporate(2,183)(1,656)
Total operating earnings/(loss)$(632)$310 
(1)Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18 million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during nine months ended March 31, 2022 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.
Assets by Reportable Segment
The following table presents total assets for each reportable segment and Corporate at:
(in millions)March 31,
2022		June 30,
2021
Pharmaceutical$25,470 $23,624 
Medical (1) (2)12,166 15,408 
Corporate 4,475 5,421 
Total assets$42,111 $44,453 
(1)Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.
(2)Medical reflects $1.8 billion of goodwill impairment charges recorded in connection with interim goodwill impairment testing for the Medical Unit at March 31, 2022, and December 31, 2021.